Methods and compositions for stabilizing dried biological materials
Inventors
Kraan, Heleen • Amorij, Jean-Pierre
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention relates to methods for producing dried formulations of biopharmaceutical agents that aim to minimize the loss of activity of the agents upon drying and to provide dried formulations with an extended shelf life. The method comprises the step of drying an aqueous solution comprising, in addition to the biopharmaceutical agent, at least an amino acid, a polyol and a metal salt. Preferably the amino acid is glutamate, the polyol is sorbitol and optionally also mannitol and the metal salt is a magnesium salt. The solution is dried by vacuum drying or by lyophilization. The methods are particularly useful for preparing dried formulations of viruses such as poliovirus or respiratory syncytial virus to be used for vaccination. The invention also relates to dried formulations prepared in accordance with the methods of the invention and to their use as medicaments, e.g. as vaccines.
Core Innovation
The invention relates to methods for producing formulations of a biopharmaceutical agent in dried form by drying an aqueous solution. The solution comprises a biopharmaceutical agent comprising poliovirus and excipients selected to stabilize activity during drying and subsequent use, including an amino acid selected from glutamate, arginine, histidine, glycine, and mixtures thereof, and a polyol comprising sorbitol and/or mannitol, together with water and at least 0.2% (w/v) of a metal salt, where the metal salt is Mg2+, Ca2+, Li+ or mixtures thereof.
In particular embodiments, the solution comprises poliovirus, glutamate, and sorbitol, and drying includes drying a solution comprising poliovirus, glutamate, sorbitol, water, and at least 0.2% (w/v) of Mg2+ metal salt. Drying can be performed by vacuum drying and/or lyophilization, and additional drying modalities are described as including air drying and spray drying.
The disclosed formulations are assessed for ability to retain activity upon reconstitution and storage. Activity retention thresholds are reported after reconstitution and after storage conditions, including retained activity at or above 50% after storage for at least one week at 45°C after reconstitution.
Claims Coverage
The document includes two independent claims covering a method for producing a dried biopharmaceutical formulation by drying a solution containing poliovirus together with selected amino acids, polyols, water, and specified metal salts. Across the independent claims, the core inventive features are the specific excipient combination and the requirement for a metal salt at a minimum level.
Drying a poliovirus solution with amino acid and polyol plus specified metal salt
A method for producing a formulation of a biopharmaceutical agent comprising drying a solution comprising a biopharmaceutical agent comprising poliovirus, an amino acid selected from glutamate, arginine, histidine, glycine, and mixtures thereof, a polyol comprising sorbitol and/or mannitol, and at least 0.2% (w/v) of a metal salt and water, wherein the metal salt is Mg2+, Ca2+, Li+ or a mixture thereof.
Drying a poliovirus solution with glutamate, sorbitol, water and Mg2+ metal salt
A method for producing a formulation of a biopharmaceutical agent comprising drying a solution comprising poliovirus, glutamate, sorbitol, and at least 0.2% (w/v) of Mg2+ metal salt and water.
Claim coverage focuses on drying poliovirus-containing biopharmaceutical solutions using an excipient system comprising specific amino acids and sorbitol/mannitol polyols, together with at least 0.2% (w/v) metal salt, including embodiments limited to Mg2+ with glutamate and sorbitol. Dependent claims further define component constraints, acceptable drying modalities, and quantitative activity-retention performance requirements after reconstitution and storage, including comparative multi-serotype activity-loss limits.
Stated Advantages
Retains at least 50% of the activity of the biopharmaceutical agent after reconstitution following storage for at least one week at 45°C.
Provides comparative multi-serotype formulations in which loss-of-activity differences are less than 50% and retained activity is expressed relative to a least-loss agent set at 100%.
Documented Applications
Stabilized dried formulations of inactivated poliovirus (including trivalent IPV / multiple serotypes) assessed for activity retention after reconstitution and storage.
Stabilized dried formulations are described for RSV in the provided content summary.
Interested in licensing this patent?